NCT03103412View on ClinicalTrials.gov

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

November 8, 2017

Study Completion Date

November 8, 2017

Conditions
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
Interventions
DRUG

TD-3504

TD-3504

DRUG

15N2-tofacitinib

15N2-tofacitinib

DRUG

Placebo

Placebo

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT03103412 - TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) | Biotech Hunter | Biotech Hunter